SEE: A Checklist For Successful Medical Technology Investing
The Worst Results In Quite A While...
Intuitive warned investors about two weeks ago that the second quarter results were going to be substantially weaker than expected. Making matters worse, though, were a big a cut to guidance and a warning that growth in Japan may well be on hold for two years.
Best Forestry Companies To Watch In Right Now: Five Prime Therapeutics Inc (FPRX)
Five Prime Therapeutics, Inc., incorporated on December 20, 2001, is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company�� advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.
FP-1039
FP-1039 is a protein therapeutic, which includes the extracellular part of FGFR1. FP-1039 acts as an inhibitor of FGFs, because the FGFR1 portion of the molecule binds to FGFs and prevents them from binding to FGFR1 on tumor and blood vessel cells. Because FGF proteins circulating in the blood are called ligands, FP-1039 is called a ligand trap. FP-1039 also includes a portion of an antibody called the Fc region. In preclinical testing, it observed inhibition of tumor growth with single-agent FP-1039, particularly in tumors withFGFR1 gene amplification, including squamous NSCLC and SCLC.
FPA008
FPA008 is an antibody that inhibits CSF1R and is being developed to treat patients with RA. FPA008 also has the potential to treat patients with other inflammatory diseases, including lupus nephritis, psoriatic arthritis, ankylosing spondylitis, fibrosis, inflammatory bowel disease and multiple sclerosis. These are chronic, incurable disorders with serious medical complications and disability for ! which better therapies with novel mechanisms of action are needed. FPA008 is an anti-CSF1R antibody, which it designed to block the ability of IL-34 and CSF1 to bind to and activate CSF1R. FPA008 reduces the numbers and activity of monocytes and macrophages that cause disease, and prevents the production and release of inflammatory factors. The Company and others has demonstrated that both IL-34 and CSF1 are present at increased levels in the inflamed joints of patients with RA.
FPA144
FPA144 is a monoclonal antibody directed against a form of FGFR2, or FGFR2b. When the FGFR2 gene is amplified by cancer cells, the FGFR2b protein is expressed at abnormally high levels on the tumor�� surface. This occurs in some patients with gastric and lower esophageal cancers. The tumor cells that have too much FGFR2b protein on their surface can be identified by special staining tests performed on the tumor. Because FGFR2b is the target for FPA144, patients��tumors can be screened for this protein, helping to identify the patients most likely to respond to FPA144 treatment.
Advisors' Opinion:- [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]
Among the companies with shares expected to actively trade in Monday’s session are Keurig Green Mountain Inc.(GMCR), JA Solar Holdings Co.(JASO) and Five Prime Therapeutics Inc.(FPRX)
- [By Monica Gerson]
Breaking news
Alcoa (NYSE: AA) is investing US$13 million to expand its wheel manufacturing plant in Europe, to meet growing demand for its lightweight, durable, low-maintenance aluminum truck wheels. To read the full news, click here. L & L Energy (NASDAQ: LLEN) announced today that its Special Independent Committee has appointed Mr. Nicholas Chen, Managing Partner at Pamir Law Group, to replace Mr. Mark Bartlett. To read the full news, click here. Five Prime Therapeutics (NASDAQ: FPRX) and Bristol-Myers Squibb (NYSE: BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform. To read the full news, click here. First Solar (NASDAQ: FSLR) on Sunday announced the completion of the 1.3MW(DC) solar photovoltaic (PV) power plant at Kitakyushu-shi. Powered by First Solar FS Series 3 Black PV modules, the plant will generate approximately 1,400 MWh of clean and safe solar electricity per year. To read the full news, click here.Posted-In: Credit Suisse US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
Top 5 Medical Stocks To Invest In Right Now: ANI Pharmaceuticals Inc (ANIP)
ANI Pharmaceuticals, Inc., incorporated on April 11, 2001, is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173, 00 square feet, the Company manufactures oral solid dose products, as well as liquids and topicals, including narcotics. Its other products include The Food and Drug Administration (FDA) approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. In December 2013, the Company acquired 31 generic drug products from Teva Pharmaceuticals, which includes 20 solid-oral immediate release products, four extended release products and seven liquid products.
The Company performs contract manufacturing for other pharmaceutical companies. It has launched three products and has 11 products in development. The Company�� targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities.
Advisors' Opinion:- [By Lisa Levin]
ANI Pharmaceuticals (NASDAQ: ANIP) shares climbed 9.42% to $20.79. The volume of ANI Pharmaceuticals shares traded was 651% higher than normal. ANI Pharmaceuticals shares have jumped 121.45% over the past 52 weeks, while the S&P 500 index has surged 25.37% in the same period.
- [By Ben Levisohn]
ANI Pharmaceuticals (ANIP) has climbed 8.9% to $18.80 after it said it would buy 31 generic drugs from Teva Pharmaceuticals (TEVA). Teva’s shares are little changed in pre-open trading.
- [By Monica Gerson]
ANI Pharmaceuticals (NASDAQ: ANIP) reported that it has bought 31 generic drug products from Teva Pharmaceuticals (NYSE: TEVA) for $12.5 million in cash and a percentage of future gross profits. ANI Pharmaceuticals shares surged 5.14% to $18.00 in the after-hours trading session.
Top 5 Medical Stocks To Invest In Right Now: Durata Therapeutics Inc (DRTX)
Durata Therapeutics, Inc., incorporated on November 4, 2009, is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.
As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin. Dalbavancin achieved its primary efficacy endpoint of non-inferiority in each of these three completed Phase III clinical trials when compared to linezolid, cefazolin or vancomycin, three of the standard-of-care agents for uncomplicated skin and skin structure infections (uSSSI), and complicated skin and skin structure infections (cSSSI). Its two ongoing Phase III clinical trials are designed to compare dalbavancin to vancomycin, with an option to switch to oral linezolid, under the new FDA draft guidance.
The Company competes with Pfizer, Cubist Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., Sanofi-Aventis Ltd., The Medicines Company, Trius Therapeutics, Inc., Cempra, Inc., Rib-X Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc., Nabriva Therapeutics AG, Tetraphase Pharmaceuticals, Inc. and Furiex Pharmaceuticals, Inc.
Advisors' Opinion:- [By Lisa Levin]
Durata Therapeutics (NASDAQ: DRTX) shares climbed 5.30% to $14.18. The volume of Durata Therapeutics shares traded was 861% higher than normal. The FDA Advisory Committee unanimously recommended the approval of Durata's Dalvance.
Top 5 Medical Stocks To Invest In Right Now: Medifocus Inc (MDFZF)
Medifocus Inc.(Medifocus) is a Canada-based company. The Company is engaged in the business of development and commercialization of minimally invasive, focused-heat tumor targeted cancer treatment devices and systems. Medifocus operates through its wholly owned subsidiary, Celsion (Canada) Limited (Celsion). Celsion had purchased from Celsion Corporation (United States), all of the assets relating to breast cancer Microfocus APA 1000 System (System), consisting of the microwave machine, the adaptive phased array (APA) technology licensed from Massachusetts Institute of Technology (MIT). The Company focuses on breast cancer treatment by using microwave heating to enhance neoadjuvant chemotherapy to provide tumor shrinkage and control. Advisors' Opinion:- [By Peter Graham]
Small cap stocks KBridge Energy Corp (OTCMKTS: BMMCF), Medifocus Inc (OTCMKTS: MDFZF) and Inscor Inc (OTCMKTS: IOGA) have been getting some attention lately in various investment newsletters and some of it is deserved as the first stock sank 35% on Friday, the second one recently released its financials (which did show a big improvement, but there is also a big catch for investors) and the third one has been the subject of a very aggressive promotional campaign. But are any of these three small caps really all that hot for investors? Here is a quick reality check:
- [By EquityOptionsGuru]
Over the past few years, and especially months, biotechnology stocks have been soaring on heightened investor expectations. Investors looking for a unique opportunity to participate in a massive bull rally over the next few years might want to pay special attention to one small but growing company called Medifocus (OTCMKTS:MDFZF).
No comments:
Post a Comment